UB Paderborn / Katalog / Suche / in CDI

Direct‐Acting Antivirals in Hepatitis C Virus‐Associated Diffuse Large B‐cell Lymphomas

The oncologist (Dayton, Ohio), 2019-08, Vol.24 (8), p.e720-e729

2019

Link zum Volltext

Verfügbarkeit prüfen

Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor

Leukemia & lymphoma, 2014-02, Vol.55 (2), p.331-336

2014

Link zum Volltext

Verfügbarkeit prüfen

The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era

Mediterranean journal of hematology and infectious diseases, 2016-09, Vol.8 (1), p.e2016045-e2016045

2016

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study

Cancer medicine (Malden, MA), 2020-11, Vol.9 (22), p.8468-8479

2020

Link zum Volltext

Verfügbarkeit prüfen

P646: VENETOCLAX RETREATMENT AFTER MRD‐GUIDED VENETOCLAX +/‐ IBRUTINIB: THE IMPROVE STUDY COHORT

HemaSphere, 2023-08, Vol.7 (S3), p.e8082529-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies

British journal of haematology, 2022-02, Vol.196 (3), p.548-558

2022

Link zum Volltext

Verfügbarkeit prüfen

Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL)

Leukemia, 2020-09, Vol.34 (9), p.2531-2532

2020

Link zum Volltext

Verfügbarkeit prüfen

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Leukemia, 2021-12, Vol.35 (12), p.3444-3454

2021

Link zum Volltext

Verfügbarkeit prüfen

Allogeneic transplantation for Hodgkin’s lymphoma

British journal of haematology, 2011-02, Vol.152 (3), p.261-272

2011

Link zum Volltext

Verfügbarkeit prüfen

Outcome of follicular lymphoma (FL) patients in maintenance with antiCD20 monoclonal antibodies (MoAb) in SARS-Cov2 era

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e19544-e19544

2022

Link zum Volltext

Verfügbarkeit prüfen

Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

Blood, 2022-12, Vol.140 (22), p.2348-2357

2022

Link zum Volltext

Verfügbarkeit prüfen

Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma

Digestive and liver disease, 2019-05, Vol.51 (5), p.719-723

2019

Link zum Volltext

Verfügbarkeit prüfen

Intention-to-Treat Analysis of Allogeneic Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Non-Hodgkin Lymphomas: A Large Italian Single-Center Experience

Blood, 2017-12, Vol.130, p.3322-3322

2017

Link zum Volltext

Verfügbarkeit prüfen

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report

Blood, 2020-08, Vol.136 (6), p.763-766

2020

Link zum Volltext

Verfügbarkeit prüfen

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Blood, 2019-11, Vol.134 (Supplement_1), p.5619-5619

2019

Link zum Volltext

Verfügbarkeit prüfen

Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis

Bone marrow transplantation (Basingstoke), 2018-03, Vol.53 (3), p.246-254

2018

Link zum Volltext

Verfügbarkeit prüfen

ENEA, a peach and apricot IgE-binding protein cross-reacting with the latex major allergen Hev b 5

Molecular immunology, 2019-08, Vol.112, p.347-357

2019

Link zum Volltext

Verfügbarkeit prüfen

Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy

Leukemia, 2020-09, Vol.34 (9), p.2531-2532

2020

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

Direct‐Acting Antivirals in Hepatitis C Virus‐Associated Diffuse Large B‐cell Lymphomas

Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability

Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor

The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs Era

Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real‐world setting. A GIMEMA‐ERIC and US study

P646: VENETOCLAX RETREATMENT AFTER MRD‐GUIDED VENETOCLAX +/‐ IBRUTINIB: THE IMPROVE STUDY COHORT

T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies

Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study

Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy : On behalf of CLL commission of Lombardy Hematology Network (REL)

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study

Allogeneic transplantation for Hodgkin’s lymphoma

Outcome of follicular lymphoma (FL) patients in maintenance with antiCD20 monoclonal antibodies (MoAb) in SARS-Cov2 era

Dose-adjusted EPOCH and rituximab for the treatment of double expressor and double-hit diffuse large B-cell lymphoma: impact of TP53 mutations on clinical outcome

Minimal residual disease–driven treatment intensification with sequential addition of ibrutinib to venetoclax in R/R CLL

Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma

Intention-to-Treat Analysis of Allogeneic Stem Cell Transplantation for Relapsed/Refractory Peripheral T-Cell Non-Hodgkin Lymphomas: A Large Italian Single-Center Experience

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report

Continuous Venetoclax in Previously Untreated Patients with Chronic Lymphocytic Leukemia and TP53 Abnormalities. a Study of the Italian Campus CLL

Comparative evaluation of biological human leukocyte antigen DPB1 mismatch models for survival and graft- versus -host disease prediction after unrelated donor hematopoietic cell transplantation

The Real Life Accessibility to CAR T-Cell Therapy: Current Experience in the Only Active Center in Italy

Plerixafor in poor mobilizers with non-Hodgkin's lymphoma: a multi-center time-motion analysis

ENEA, a peach and apricot IgE-binding protein cross-reacting with the latex major allergen Hev b 5

Continuous venetoclax in treatment‐naive TP 53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study

Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL)

Reply to "CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report" Analysis of six hematological centers in Lombardy

Suchergebnisse filtern